Infectious Disease Book


Second-Generation Glycopeptide Antibiotic

Aka: Second-Generation Glycopeptide Antibiotic, Semi-Synthetic Glycopeptide Antibiotic, Lipoglycopeptide Antibiotic, Dalbavancin, Dalvance, Oritavancin, Orbactiv
  1. Mechanism
    1. Decreases Bacterial cell wall synthesis
    2. Similar coverage and mechanism to Vancomycin
    3. Long-acting agents, with a single parenteral dose covering entire antibiotic course
  2. Indications
    1. Refractory Skin and Soft Tissue Infections with failure to respond to maximal oral antibiotic coverage
  3. Preparations
    1. Dalbavancin (Dalvance)
      1. Infused over 30 minutes weekly
    2. Oritavancin (Orbactiv)
      1. Infused over 3 hours
      2. Single dose may be sufficient for MRSA Cellulitis
      3. Contraindicated with Warfarin or Heparin use
  4. Disadvantages
    1. Expensive ($2500 to $9500 per single dose)
  5. References
    1. (2014) Presc Lett 21(8): 43

dalbavancin (C1172636)

Concepts Antibiotic (T195) , Amino Acid, Peptide, or Protein (T116)
MSH C469289
LNC LP35848-8, MTHU018746
English dalbavancin [Chemical/Ingredient], Dalbavancin, DALBAVANCIN, dalbavancin
Derived from the NIH UMLS (Unified Medical Language System)

You are currently viewing the original '\legacy' version of this website. Internet Explorer 8.0 and older will automatically be redirected to this legacy version.

If you are using a modern web browser, you may instead navigate to the newer desktop version of fpnotebook. Another, mobile version is also available which should function on both newer and older web browsers.

Please Contact Me as you run across problems with any of these versions on the website.

Navigation Tree